|
Jul 21
|
NodThera Announces Appointment of Dr. Jyothis George as Chief Medical Officer
|
|
Jul 19
|
Why Amgen (AMGN) Could Be a Hidden Gem Among Dividend Pharma Stocks in 2025
|
|
Jul 18
|
Amgen (AMGN) Declines More Than Market: Some Information for Investors
|
|
Jul 18
|
HSBC Trims Amgen (AMGN) Price Target, Maintains Buy Rating
|
|
Jul 18
|
EBay Stock: How To Find & Own America's Greatest Opportunities
|
|
Jul 17
|
Can Amgen (AMGN) Keep the Earnings Surprise Streak Alive?
|
|
Jul 17
|
Eli Lilly vs. Merck: Which Drug Giant Appears Better Poised Today?
|
|
Jul 17
|
Thyroid Gland Disorders Diagnostics and Treatment Market Analysis Report 2024-2030 | Incorporation of AI and Advanced Therapeutics Fueling Opportunities
|
|
Jul 2
|
mAbxience Announces European Commission Approval of Denosumab Biosimilars
|
|
Jul 2
|
This GLP-1 Stock's Bad News Could Be a Big Win for Eli Lilly and Novo Nordisk
|
|
Jul 1
|
Trading Rotation Kicks Off 2nd Half of 2025
|
|
Jul 1
|
Amgen and Zai Lab’s trial of gastric cancer therapy meets primary endpoint
|
|
Jun 30
|
Can Protagonist Take On Eli Lilly's Next-Generation Obesity Treatment?
|
|
Jun 30
|
AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR BEMARITUZUMAB IN FIBROBLAST GROWTH FACTOR RECEPTOR 2b (FGFR2b) POSITIVE FIRST-LINE GASTRIC CANCER
|
|
Jun 30
|
2 Dividend Stocks to Buy on the Dip and Hold Forever
|
|
Jun 28
|
Jim Cramer Says That Amgen’s Stock “Did Not Deserve to Get Hit This Hard”
|
|
Jun 27
|
Amgen Looks to Take Share of Booming Obesity Space: Will It Succeed?
|
|
Jun 27
|
Here's Why Amgen (AMGN) is a Strong Growth Stock
|
|
Jun 27
|
Cancer Vaccine (Preventative, Therapeutic) Market Research 2025 with Analyst Recommendations-Leveraging AI and Bioinformatics for Precision Development / Pursue Fast-Track and Orphan Drug Designations
|
|
Jun 26
|
5 Insightful Analyst Questions From Amgen’s Q1 Earnings Call
|